In this edition of The Motley Fool's health care show Market Checkup, health care analysts David Williamson and Max Macaluso discuss Gilead Sciences, the biggest biotech company in the world.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
This edition of the Fool's health care show focuses on biotech company Gilead.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Merck
MRK
$78.95
(0.15%)
$0.12
Eli Lilly
LLY
$775.45
(-2.47%)
$-19.67
Johnson & Johnson
JNJ
$152.45
(0.29%)
$0.44
Pfizer
PFE
$24.20
(-0.17%)
$0.04
Novartis Ag
NVS
$120.30
(-0.02%)
$0.02
Bristol Myers Squibb
BMY
$46.34
(-0.67%)
$0.31
Gilead Sciences
GILD
$110.71
(2.87%)
$3.09
GSK
GSK
$38.58
(0.08%)
$0.03
Vertex Pharmaceuticals
VRTX
$441.24
(-0.49%)
$-2.16
Amgen
AMGN
$277.13
(-0.71%)
$-1.98
AbbVie
ABBV
$182.31
(-2.40%)
$-4.48
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
Hims & Hers Stock Investors Need to Know This Before Buying or Selling This Growth Stock
Hims & Hers Stock Financial Analysis Following Huge Stock Price Crash
Which Stock Will Dominate the Weight Management Market Through 2030?
3 No-Brainer Stocks to Buy for Under $100 Right Now
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.